Tone mix
Week by week 52 weeks
Share of Arcus Biosciences, Inc.'s 143 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Apr 20, 2026 · tone -66Arcus Biosciences Discontinues Lung Cancer Trial With Gilead-98
- Week of Feb 9, 2026 · tone -100Arcus Biosciences (NYSE:RCUS) Downgraded by Wells Fargo & Company to Equal Weight-85
- Week of Oct 12, 2026 · tone +100Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rated "Moderate Buy" by Sell-Side Brokerages+75
- Week of Jun 9, 2025 · tone +99Arcus Biosciences Announces New Employment Inducement Grants+74
- Week of Mar 30, 2026 · tone +80Arcus Biosciences (NYSE:RCUS) Upgraded at Truist Financial+71
- Week of Mar 2, 2026 · tone +50Arcus Biosciences Q4 Earnings Call Highlights+62
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Arcus Biosciences, Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 6 | +18 |
| Last 30 sessions | 9 | +23 |
| Last 90 sessions | 32 | +40 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Tuesday, October 27, 2026
1 headline, average tone -100: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.dailypolitical.com · 1 outletArcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street ZenNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Arcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street Zen | www.dailypolitical.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletArcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Arcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00 | www.dailypolitical.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
3 headlines, average tone +66: 2 positive, 1 neutral and 0 negative. Showing all 3.
- www.prnewswire.com · 2 outletsKuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmNeutral
- www.themarketsdaily.com · 1 outletArcus Biosciences (NYSE:RCUS) Stock Gets Price Target Boost from Truist FinancialPositive
- www.themarketsdaily.com · 1 outletArcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Wedbush Analyst SaysPositive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm | www.prnewswire.com | 2 | Neutral |
| Arcus Biosciences (NYSE:RCUS) Stock Gets Price Target Boost from Truist Financial | www.themarketsdaily.com | 1 | Positive |
| Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Wedbush Analyst Says | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
1 headline, average tone -93: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.investors.com · 1 outletArcus Biosciences Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer DataNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Arcus Biosciences Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer Data | www.investors.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 20, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletInvivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical ContrastNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical Contrast | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Arcus Biosciences, Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.